Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension

Figures & data

Figure 1 Change from baseline blood pressure measures at 6 weeks.

Notes: ^aP < 0.001 compared to chlorthalidone 25 mg daily, mean daytime systolic blood pressure was measured from 6 am to 10 pm, mean nighttime systolic blood pressure was measured from 12 am to 6 am, trough SBP was measured 22 to 24 hours after the dose was given.¹⁵
Abbreviations: AZL, azilsartan; CLD, chlorthalidone; DBP, diastolic blood pressure; SBP, systolic blood pressure.

Table 1 Change in trough SBP of combinations when compared to the monotherapy components at week 8

LSM SBP reduction (mmHg)	No azilsartan	Azilsartan 20 mg	Azilsartan 40 mg	Azilsartan 80 mg
No chlorthalidone	–	−12.1	−12.8	−15.1
Chlorthalidone 12.5 mg	−12.7	−22.9a,b	−24.4a,b	−26.3a,b
Chlorthalidone 25 mg	−15.9	−26.3a,b	−29.8a,b	−28.0a,b

Notes:

a P < 0.001 compared to chlorthalidone component;

b P < 0.001 compared to the azilsartan component.

Copyright © 2011. Reprinted with permission from John Wiley and Sons. American Society of Hypertension. Twenty-Sixth Annual Scientific Meeting and Exposition [featured posters, poster 182]. J Clin Hypertens. 2011;13:12–163. Available from: http://onlinelibrary.wiley.com/doi/10.1111/j.1751-7176.2011.00459.x/abstract. Accessed January 2011.¹⁶

Abbreviations: LSM, least squares mean; SBP, systolic blood pressure.

Table 2 Effects of complete blood pressure therapy (initial + follow-up) on the risk of cardiovascular events

Initial therapy	Therapy during follow-up	OR	95% CI
Monotherapy	Monotherapy	1.00	Reference
	Combination therapy	1.00	0.91 to 1.10
Combination therapy	Monotherapy	0.96	0.86 to 1.07
	Combination therapy	0.74	0.65 to 0.85

Copyright © 2011, Reprinted with permission from American Heart Association. Corrao G, Nicotra F, Parodi A, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension. 2011;58(4):566–572.²⁹

Abbreviations: CI, confidence interval; OR, odds ratio.

Clinicaltrials.govEfficacy and safety of azilsartan medoxomil co- administered with chlorthalidone in participants with essential hypertension. Study NCT00591773 Available from: http://clinicaltrials.gov/ct2/show/NCT00591773?term=NCT00591773&rank=1Accessed December 13, 2011

 Google Scholar

American Society of HypertensionTwenty-Sixth Annual Scientific Meeting and Exposition [featured posters, poster 182]J Clin Hypertens201113S1A12A12163 Available from: http://onlinelibrary.wiley.com//10.1111/j.1751-7176.201100459.x/abstractAccessed January 2011

 Google Scholar

CorraoGNicotraFParodiACardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practiceHypertension201158456657221825231

 PubMed Web of Science ®Google Scholar